Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a non-standard combination of two products: - **Aminocaproic acid** is an antifibrinolytic agent used to control bleeding caused by excessive fibrinolysis. It works by inhibiting plasminogen activation, thereby reducing the breakdown of blood clots. It is primarily indicated for acute bleeding disorders, including those occurring during or after surgery, in certain cancers, and in specific gynecological conditions[1][5][6]. - **Vanicream** is a topical moisturizer formulated to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations. It contains emollients that help hydrate and protect the skin barrier but does not have pharmacological activity related to hemostasis or systemic disease[8]. There are no known approved pharmaceutical products combining aminocaproic acid with Vanicream as a single formulation; their uses are distinct—aminocaproic acid for systemic antifibrinolytic therapy and Vanicream for topical dermatologic care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminocaproic acid + Vanicream.